Lifetime Management for Aortic Stenosis: Strategy and Decision-Making in the Current Era.

Aortic stenosis, the most common valvular disease in the Western world, has traditionally been treated with surgical aortic valve replacement (SAVR) but is increasingly treated by transcatheter aortic valve replacement (TAVR). Whereas patients older than 65 years are preferably treated with bioprosthetic tissue valves, there is considerable uncertainty in the choice between TAVR and SAVR. We present various considerations for optimizing the lifelong management of patients receiving bioprosthetic valves (SAVR or TAVR). To maximize life expectancy and to minimize cumulative lifetime risk, we suggest decision-making individualized for patient anatomy and overall (current and future) risk.
Competing Interests: Disclosures Isaac George reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory; with Medtronic that includes: consulting or advisory; with Boston Scientific that includes: consulting or advisory; and with Abbott Vascular Inc that includes: consulting or advisory. Andrei Pop reports a relationship with Edwards Lifesciences that includes: consulting or advisory; with Inari Medical that includes: consulting or advisory; and with Shockwave that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)